Ally Bridge Group (Ny) Llc
- Regulatory AUM
- $219M
- Discretionary
- $219M
- Clients
- 3
- Avg AUM / client
- $73.0M
- Accounts
- 3
- Employees
- 7
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 31, 2026
Investments (13F portfolio — 26 positions, $123,814,181)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Soleno Therapeutics Inc | COM | $13,392,000 | 400,000 | 10.8% | 6.12% |
| 2 | Praxis Precision Medicines I | COM NEW | $10,571,054 | 32,810 | 8.54% | 4.83% |
| 3 | Minerva Neurosciences Inc | COM NEW | $9,974,388 | 1,655,500 | 8.06% | 4.56% |
| 4 | Ovid Therapeutics Inc | COM | $6,256,979 | 2,818,459 | 5.05% | 2.86% |
| 5 | Compass Pathways Plc | SPONSORED ADS | $5,778,850 | 1,045,000 | 4.67% | 2.64% |
| 6 | Tarsus Pharmaceuticals Inc | COM | $5,672,259 | 80,859 | 4.58% | 2.59% |
| 7 | Solid Biosciences Inc | COM NEW | $5,522,213 | 766,974 | 4.46% | 2.52% |
| 8 | Compass Therapeutics Inc | COM | $5,290,000 | 1,000,000 | 4.27% | 2.42% |
| 9 | Promis Neurosciences Inc | COM SHS | $5,260,581 | 414,219 | 4.25% | 2.4% |
| 10 | Edgewise Therapeutics Inc | COM | $5,071,500 | 161,000 | 4.1% | 2.32% |
| 11 | Uniqure Nv | SHS | $4,905,000 | 300,000 | 3.96% | 2.24% |
| 12 | Eupraxia Pharmaceuticals Inc | COM | $4,781,115 | 660,375 | 3.86% | 2.18% |
| 13 | Cytomx Therapeutics Inc. | COM | $4,230,000 | 900,000 | 3.42% | 1.93% |
| 14 | Inventiva Sa | ADS | $4,136,415 | 745,300 | 3.34% | 1.89% |
| 15 | Perspective Therapeutics Inc | COM NEW | $3,863,743 | 926,557 | 3.12% | 1.76% |
| 16 | Abivax Sa | SPONSORED ADS | $3,753,831 | 33,712 | 3.03% | 1.71% |
| 17 | Alumis Inc | COM | $3,678,107 | 166,959 | 2.97% | 1.68% |
| 18 | Urogen Pharma Ltd | COM | $3,634,190 | 202,124 | 2.94% | 1.66% |
| 19 | Capricor Therapeutics Inc | COM NEW | $3,462,530 | 113,899 | 2.8% | 1.58% |
| 20 | Maze Therapeutics Inc | COM | $2,985,000 | 100,000 | 2.41% | 1.36% |
| 21 | Whitehawk Therapeutics Inc | COM | $2,821,890 | 817,939 | 2.28% | 1.29% |
| 22 | Inhibikase Therapeutics Inc | COM NEW | $2,226,000 | 1,325,000 | 1.8% | 1.02% |
| 23 | Replimune Group Inc | COM | $1,888,785 | 246,900 | 1.53% | 0.86% |
| 24 | An2 Therapeutics Inc | COM | $1,799,997 | 526,315 | 1.45% | 0.82% |
| 25 | Relmada Therapeutics Inc | COM | $1,465,254 | 210,525 | 1.18% | 0.67% |
Top 25 of 26 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 3 | $219M | 100.0% |
Private funds (3)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $335M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Ally Bridge Medalpha Master Fund L.P. master | Hedge Fund | Cayman Islands | $226M | 31 |
| Ally Bridge Medalpha International Fund Limited feeder | Hedge Fund | Cayman Islands | $107M | 21 |
| Ally Bridge Medalpha Us Fund L.P. feeder | Hedge Fund | Delaware | $2.0M | 9 |
People (4)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Yu, Fan, Nmn | Shareholder And Director | Jun 2013 (13y) | ≈ 56.25% – 100% via Abg Management Ltd | |
| Bendetson, Michael, Novick | Coo, Head Of Legal & Chief Compliance Officer | Feb 2021 (6y) | Less than 5% | |
| Alex, Slanix Paul, T | President & Portfolio Manager | Jan 2023 (4y) | Less than 5% | |
| Corb, Kevin, William | Chief Financial Officer | Feb 2023 (4y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Abg Management Ltd | Shareholder | Mar 2017 | A | 75% or more |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Estimated effective ownership (look-through of filed bands):
- Yu, Fan, Nmn: 75% – 100% of Abg Management Ltd × 75% – 100% direct ≈ 56.25% – 100% of the firm
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (3, $335M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Ally Bridge Medalpha Master Fund L.P. | Hedge Fund | $226M | $100K | 31 |
| Ally Bridge Medalpha International Fund Limited | Hedge Fund | $107M | $5.0M | 21 |
| Ally Bridge Medalpha Us Fund L.P. | Hedge Fund | $2.0M | $5.0M | 9 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 2.2 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗